Why Jazz Pharmaceuticals Could Be Your Next Long-Term Buy

Jazz Pharmaceuticals (JAZZ) trades around $110, down 11% year-to-date, primarily due to a substantial downward revision of its 2025 earnings guidance to $4-$5.60 from $22.50-$24, driven by $1.1 billion in one-time IPR&D and litigation charges. Despite this, the company recently secured conditional EU marketing authorization for Ziihera, a first-in-class HER2-targeted therapy with over $2 billion in estimated peak annual sales, and exhibits strong underlying fundamentals including robust revenue growth and high operating cash flow. While Jazz faces a significant debt load and historical sensitivity to market downturns, its current valuation at 5.5x trailing adjusted earnings and projected 2026 earnings rebound to $21.56 suggest it is undervalued, presenting a long-term opportunity for investors.

Analysis

Jazz Pharmaceuticals' stock performance, down 11% year-to-date to approximately $110, appears disconnected from its underlying operational strengths and pipeline developments. The primary driver of this underperformance is a significant downward revision of its 2025 earnings estimate to $4-$5.60 per share, which is a direct result of a non-recurring $1.1 billion charge for IPR&D from the Chimerix acquisition and litigation expenses. Despite this, the company's fundamentals remain robust, evidenced by a three-year revenue growth rate of 7.3% that outpaces the S&P 500 and a very strong operating cash flow margin of 38.3%. On a valuation basis, JAZZ trades at a deep discount of 5.5 times its trailing adjusted earnings of $20.19 per share, well below its four-year average P/E of 8.1x. This valuation gap is amplified by major pipeline catalysts, including the recent conditional EU approval for Ziihera, a first-in-class therapy with estimated peak sales over $2 billion, and the addition of dordaviprone with over $500 million in peak sales potential. Projections for a rebound in 2026 earnings to $21.56 further suggest the 2025 guidance is an anomaly. However, significant risks persist, namely a high debt load of $5.4 billion, resulting in an 81.6% debt-to-equity ratio, and a documented history of underperforming the broader market during downturns.

Key Decisions for Investors

• Given the stock's valuation at 5.5x trailing adjusted P/E and the market's apparent overreaction to one-time charges, long-term investors should consider the current price a compelling entry point, especially with 2026 earnings projected to rebound significantly.
• Investors must closely monitor the company's high debt load and any deleveraging strategy, as the 81.6% debt-to-equity ratio presents a material risk, particularly given the stock's historical volatility in market downturns.
• Key performance indicators to watch are the commercial success and sales ramp-up of Ziihera in the EU and pipeline progress on dordaviprone, as these are critical to validating the long-term growth thesis and justifying the 70% upside implied by analyst consensus.